Skip to Main Content

Paper Details

Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.
Proc Natl Acad Sci U S A
47
2020
AML, Acute myeloid leukemia, CTLA-4, PD-1, T cell, TIM3, acute leukemia, acute myeloid leukemia, advanced cancers, patients, persons, tumor
Bone Marrow, CTLA-4 Antigen, Cell Proliferation, Cytokines, Hepatitis A Virus Cellular Receptor 2, Humans, Leukemia, Myeloid, Acute, Programmed Cell Death 1 Receptor, T-Lymphocytes, Tumor Microenvironment
Author NameAffiliation
Adam J LambleOregon Health & Science University
Yoko KosakaOregon Health & Science University
Ted LaderasOregon Health & Science University
Allie MaffitOregon Health & Science University
Andy KaempfKnight Cancer Institute, Oregon Health & Science University
Lauren K BradyJanssen Pharmaceutical Research and Development
Weiwei WangClinical Laboratory, Xinhua Hospital, Shanghai Jiaotong University of Medicine School
Nicola LongKnight Cancer Institute, Oregon Health & Science University
Jennifer N SaultzCenter for Hematological Malignancies, Oregon Health & Science University
Motomi MoriKnight Cancer Institute, Oregon Health & Science University
T David SoongJanssen Pharmaceutical Research and Development
T David SoongJanssen Pharmaceutical Research and Development
Clare V LeFaveLabConnect LLC
Fei HuangJanssen Pharmaceutical Research and Development
Homer C AdamsJanssen Pharmaceutical Research and Development
Marc M LoriauxKnight Cancer Institute, Oregon Health & Science University
Marc M LoriauxCenter for Hematological Malignancies, Oregon Health & Science University
Cristina E TognonKnight Cancer Institute, Oregon Health & Science University
Pierrette LoKnight Cancer Institute, Oregon Health & Science University
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University
Jeffrey W TynerOregon Health & Science University
Guang FanOregon Health & Science University
Shannon K McWeeneyOregon Health & Science University
Shannon K McWeeneyKnight Cancer Institute, Oregon Health & Science University
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University
Brian J DrukerCenter for Hematological Malignancies, Oregon Health & Science University
Brian J DrukerHoward Hughes Medical Institute, Oregon Health & Science University
Evan F LindOregon Health & Science University
Evan F LindKnight Cancer Institute, Oregon Health & Science University
Evan F LindOregon Health & Science University
  • 1 - 30

Datasets

Release 1.2